NasdaqGS:GLUEBiotechs
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Johnson & Johnson MRT-2359 Trial Supply Agreement
Monte Rosa Therapeutics (GLUE) has moved into focus after signing a supply agreement with Johnson & Johnson to evaluate MRT-2359 plus ERLEADA in a planned Phase 2 trial for metastatic castration-resistant prostate cancer.
See our latest analysis for Monte Rosa Therapeutics.
Alongside the Johnson & Johnson supply agreement and fresh MRT-2359 data, Monte Rosa’s share price has eased recently. The stock has a 30 day share price return of 15% and a 90 day share price return decline of 11%. At the...